Sunesis Pharma

SNSS NASDAQ
0.8450
+0.0150
+1.81%
Closed 16:00 08/19 EDT
Open
0.8400
Prev Close
0.8300
High
0.8500
Low
0.8000
Volume
178.97K
Avg Vol (3M)
1.04M
52 Week High
2.255
52 Week Low
0.2000
% Turnover
0.16%
Market Cap
94.07M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Sunesis Pharma SNSS stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML). Vosaroxin is an anticancer quinolone derivative (AQD). The Company's other kinase inhibitor pipeline include TAK-580, SNS-062 and SNS-229. TAK-580 is an oral, investigative drug selective for pan-Raf kinase inhibition, in patients with relapsed or refractory solid tumors. SNS-062 is a non-covalently binding inhibitor of Bruton's tyrosine kinase (BTK). The Company has completed the pre-clinical studies for SNS-062. SNS-229 and SNS-510 are two PDK1 inhibitors. PDK1 is a kinase and mediator of Phosphoinositide 3-kinase/AKT (PI3K/AKT) signaling, which is a pathway involved in cell growth, differentiation, survival and migration.
MORE >

Recently

Name
Price
%Change